PureTech Health spinout Celea Therapeutics will apply the financing toward a Phase 3 test of its idiopathic pulmonary (IPF) drug, deupirfenidone. The pivotal study will test the oral small molecule head-to-head against a standard of care IPF drug.
The post Lung-Focused Celea Secures $180M for Pivotal Test of Pulmonary Fibrosis Drug appeared first on MedCity News.
